SAN DIEGO, CA, June 16, 2008 -- VaxInnate Corporation announced today that it will discuss its novel proprietary technology for producing seasonal and pandemic influenza vaccines during BIO 2008 here this week.
VaxInnate will participate in the following three BIO 2008 panel discussions:
On Tuesday, June 17th
On Thursday, June 19th
VaxInnate's novel technology has the potential to dramatically improve the potency, manufacturing capacity and cost-effectiveness of influenza vaccines.
VaxInnate's approach to developing and producing influenza vaccines is based upon a proprietary combination of toll-like receptor (TLR) mediated immune enhancement and recombinant bacterial production of vaccine antigen. This proprietary technology could significantly reduce the time required to produce supplies of influenza vaccine sufficient to meet national and even global needs.
VaxInnate's use of bacterial expression for production of influenza vaccines does not require costly expansion of manufacturing capacity, as do other influenza vaccine products. Due to its efficiency and transferability, VaxInnate's flu vaccine could instead be produced in existing biotechnology facilities that have microbial production capacity.
No other vaccine technology in use or in development today has these same potential capabilities.
Results of a Phase I study of VaxInnate's M2e universal vaccine candidate will be available this summer. The company plans to present the study data at a major scientific conference later this year and publish the data in a peer-reviewed journal.
|Contact: Janet Skidmore|